# A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

> **NCT05259033** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 683 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** IcoSema
- **DRUG:** Semaglutide 1 mg

## Key facts

- **NCT ID:** NCT05259033
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-11
- **Primary completion:** 2023-12-13
- **Final completion:** 2024-01-16
- **Target enrollment:** 683 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05259033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05259033, "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05259033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*